72. Pituitary ADH secretion disorder Clinical trials / Disease details
Clinical trials : 40 / Drugs : 28 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04447911 (ClinicalTrials.gov) | February 4, 2021 | 10/6/2020 | Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia | Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study) | Hyponatremia;SIADH;Liver Failure;Kidney Failure | Drug: Empagliflozin 25 MG;Drug: Placebo | University Hospital, Basel, Switzerland | Luzerner Kantonsspital | Recruiting | 18 Years | N/A | All | 172 | Phase 4 | Switzerland |
| 2 | NCT03202667 (ClinicalTrials.gov) | December 15, 2017 | 27/6/2017 | Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study | Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study | SIAD - Syndrome of Inappropriate Antidiuresis;Hyponatremia | Drug: Empagliflozin 25mg;Drug: Placebo | University Hospital, Basel, Switzerland | NULL | Completed | 18 Years | N/A | All | 17 | Phase 2/Phase 3 | Switzerland |
| 3 | NCT02874807 (ClinicalTrials.gov) | September 5, 2016 | 17/8/2016 | Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study | Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study | SIADH | Drug: Empagliflozin;Other: Placebo | University Hospital, Basel, Switzerland | NULL | Completed | 18 Years | 84 Years | All | 88 | Phase 2/Phase 3 | Switzerland |
| 4 | NCT02729766 (ClinicalTrials.gov) | March 2016 | 24/3/2016 | Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Inappropriate ADH Syndrome | Other: Induced hypotonic hyponatremia - SIAD model;Drug: Empagliflozin 25mg Tbl;Drug: Placebo P-Tablet | University Hospital, Basel, Switzerland | NULL | Completed | 18 Years | 65 Years | Both | 15 | Phase 2/Phase 3 | Switzerland |